Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
58.25
-1.71 (-2.84%)
Jan 17, 2025, 4:00 PM EST - Market closed
Disc Medicine Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 73.7, with a low estimate of 40 and a high estimate of 118. The average target predicts an increase of 26.53% from the current stock price of 58.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2024.
Analyst Ratings
The average analyst rating for Disc Medicine stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
Buy | 5 | 5 | 6 | 6 | 6 | 6 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 10 | 10 | 10 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Stifel | Stifel | Strong Buy Maintains $79 → $90 | Strong Buy | Maintains | $79 → $90 | +54.52% | Dec 10, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $118 | Strong Buy | Reiterates | $118 | +102.59% | Dec 9, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $70 → $118 | Strong Buy | Maintains | $70 → $118 | +102.59% | Nov 13, 2024 |
Scotiabank | Scotiabank | Buy Maintains $62 → $70 | Buy | Maintains | $62 → $70 | +20.18% | Nov 5, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +20.18% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.20
from -3.42
EPS Next Year
-5.19
from -4.20
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 57.1M | |||
Avg | n/a | n/a | 21.2M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -4.07 | -4.31 | -3.18 | |||
Avg | -4.20 | -5.19 | -5.54 | |||
Low | -4.37 | -6.04 | -8.05 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.